• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Aradigm to Hold 2007 Third Quarter Financial Results Conference Call November 8

Posted on: Thursday, 25 October 2007, 18:00 CDT

Aradigm Corporation (OTCBB: ARDM) (the "Company"), a specialty pharmaceutical company, will release its 2007 third quarter financial results after the market close on Thursday, November 8, 2007.

Aradigm's President and Chief Executive Officer Igor Gonda, Ph.D., and Company management will host an investment-community conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Thursday, November 8, 2007 to discuss the financial results, provide a business update and to answer questions.

To participate in the live call by telephone, please dial (800) 323-0845 from the U.S., and for international callers, please dial (706) 634-8407. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 21379983.

Individuals interested in listening to the conference call via the Internet may do so by visiting www.aradigm.com. An archived presentation will be available on the Web site for 14 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx® insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. More information about Aradigm can be found at www.aradigm.com.

Aradigm and AERx are registered trademarks and the Aradigm Logo is a trademark of Aradigm Corporation.

SOURCE: Aradigm

Source: Business Wire

More News in this Category